What does Kiora Pharmaceuticals, Inc. do?
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of…
What is Kiora Pharmaceuticals, Inc.'s P/E and P/B ratio?
Kiora Pharmaceuticals, Inc. has a P/E ratio of -0.9 and a P/B ratio of 0.61.
What is Kiora Pharmaceuticals, Inc.'s debt-to-equity ratio?
Kiora Pharmaceuticals, Inc. has a debt-to-equity ratio of 0.02.
How much does Kiora Pharmaceuticals, Inc. owe compared with what it owns?
Kiora Pharmaceuticals, Inc. owes $0.29 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Kiora Pharmaceuticals, Inc.'s Positivity rank?
Kiora Pharmaceuticals, Inc. is ranked #3,974 of 6,774 companies globally and #1,873 of 4,000 in United States on PositoAI, with a Positivity Score of 20,045.
Does Kiora Pharmaceuticals, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Kiora Pharmaceuticals, Inc..
Where can I read the latest news about Kiora Pharmaceuticals, Inc.?
Recent headlines about Kiora Pharmaceuticals, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Kiora Pharmaceuticals, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Kiora Pharmaceuticals, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.